Stock Scorer

Elanco Animal Health Inc (ELAN)

Elanco Animal Health Inc reported revenue of 1.4B USD for the quarter ending 30 June 2026, up 10.2% from 1.2B a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 1.4B +10.2%
Gross Profit Q2 '26 · ending 30 June 2026 798M +11.9%
Net Income Q2 '26 · ending 30 June 2026 54M +390.9%
Cost of Revenue Q2 '26 · ending 30 June 2026 570M +8.0%
Operating Cash Flow Q2 '26 · ending 30 June 2026 277M +16.9%
Free Cash Flow Q2 '26 · ending 30 June 2026 244M +35.6%
Shares Outstanding Q2 '26 · ending 30 June 2026 505.9M +1.4%
EPS Q2 '26 · ending 30 June 2026 -0.41 -147.7%

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 4.7B—-232M284M
20242024-12-31 4.4B—338M394M
20232023-12-31 4.4B—-1.2B131M
20222022-12-31 4.4B—-78M281M
20212021-12-31 4.8B—-483M324M
20202020-12-31 3.3B—-574M-176M
20192019-12-31 3.1B—68M84M
20182018-12-31 3.1B—86.5M352.8M
20172017-12-31 2.9B—-310.7M75.2M
20162016-12-31 2.9B—-47.9M45.6M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-301.4B
Q1 '262026-03-311.4B
Q4 '252025-12-311.1B
Q3 '252025-09-301.1B
Q2 '252025-06-301.2B
Q1 '252025-03-311.2B
Q4 '242024-12-311B
Q3 '242024-09-301B
Q2 '242024-06-301.2B
Q1 '242024-03-311.2B
Q4 '232023-12-311B
Q3 '232023-09-301.1B
Q2 '232023-06-301.1B
Q1 '232023-03-311.3B
Q4 '222022-12-31985M
Q3 '222022-09-301B
Q2 '222022-06-301.2B
Q1 '222022-03-311.2B
Q4 '212021-12-311.1B
Q3 '212021-09-301.1B

Gross Profit Quarterly

PeriodEndingGross Profit
Q2 '262026-06-30798M
Q1 '262026-03-31785M
Q4 '252025-12-31589M
Q3 '252025-09-30607M
Q2 '252025-06-30713M
Q1 '252025-03-31684M
Q4 '242024-12-31519M
Q3 '242024-09-30538M
Q2 '242024-06-30689M
Q1 '242024-03-31690M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-3054M
Q1 '262026-03-3157M
Q4 '252025-12-31-276M
Q3 '252025-09-30-34M
Q2 '252025-06-3011M
Q1 '252025-03-3167M
Q4 '242024-12-31-8M
Q3 '242024-09-30364M
Q2 '242024-06-30-50M
Q1 '242024-03-3132M
Q4 '232023-12-31-141M
Q3 '232023-09-30-1.1B
Q2 '232023-06-30-97M
Q1 '232023-03-31103M
Q4 '222022-12-31-54M
Q3 '222022-09-30-65M
Q2 '222022-06-30-10M
Q1 '222022-03-3151M
Q4 '212021-12-31-105M
Q3 '212021-09-30-104M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-30570M
Q1 '262026-03-31586M
Q4 '252025-12-31555M
Q3 '252025-09-30530M
Q2 '252025-06-30528M
Q1 '252025-03-31509M
Q4 '242024-12-31501M
Q3 '242024-09-30492M
Q2 '242024-06-30495M
Q1 '242024-03-31515M
Q4 '232023-12-31516M
Q3 '232023-09-30487M
Q2 '232023-06-30434M
Q1 '232023-03-31494M
Q4 '222022-12-31448M
Q3 '222022-09-30472M
Q2 '222022-06-30484M
Q1 '222022-03-31509M
Q4 '212021-12-31510M
Q3 '212021-09-30502M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30277M
Q1 '262026-03-3113M
Q4 '252025-12-31108M
Q3 '252025-09-30219M
Q2 '252025-06-30237M
Q1 '252025-03-31-4M
Q4 '242024-12-31177M
Q3 '242024-09-30162M
Q2 '242024-06-30200M
Q1 '242024-03-312M
Q4 '232023-12-31157M
Q3 '232023-09-30198M
Q2 '232023-06-3061M
Q1 '232023-03-31-145M
Q4 '222022-12-3113M
Q3 '222022-09-30189M
Q2 '222022-06-30312M
Q1 '222022-03-31-62M
Q4 '212021-12-31223M
Q3 '212021-09-3089M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30244M
Q1 '262026-03-31-38M
Q4 '252025-12-3146M
Q3 '252025-09-30127M
Q2 '252025-06-30180M
Q1 '252025-03-31-69M
Q4 '242024-12-31130M
Q3 '242024-09-30120M
Q2 '242024-06-30166M
Q1 '242024-03-31-22M
Q4 '232023-12-31116M
Q3 '232023-09-30165M
Q2 '232023-06-3019M
Q1 '232023-03-31-169M
Q4 '222022-12-31-87M
Q3 '222022-09-30163M
Q2 '222022-06-30286M
Q1 '222022-03-31-81M
Q4 '212021-12-31124M
Q3 '212021-09-3064M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30505.9M
Q1 '262026-03-31506M
Q3 '252025-09-30496.8M
Q2 '252025-06-30500.1M
Q1 '252025-03-31499.1M
Q3 '242024-09-30497.7M
Q2 '242024-06-30494.2M
Q1 '242024-03-31496M
Q3 '232023-09-30492.7M
Q2 '232023-06-30492.6M
Q1 '232023-03-31492.8M
Q3 '222022-09-30488.4M
Q2 '222022-06-30488.4M
Q1 '222022-03-31492.2M
Q4 '212021-12-31487.4M
Q3 '212021-09-30487.3M
Q2 '212021-06-30487.3M
Q1 '212021-03-31486.7M
Q3 '202020-09-30462.4M
Q2 '202020-06-30413.2M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-0.41
Q1 '262026-03-31-0.50
Q4 '252025-12-31-0.48
Q3 '252025-09-300.06
Q2 '252025-06-300.86
Q1 '252025-03-310.74
Q4 '242024-12-310.67
Q3 '242024-09-300.40
Q2 '242024-06-30-2.55
Q1 '242024-03-31-2.65
Q4 '232023-12-31-2.50
Q3 '232023-09-30-2.32
Q2 '232023-06-30-0.23
Q1 '232023-03-31-0.05
Q4 '222022-12-31-0.16
Q3 '222022-09-30-0.27
Q2 '222022-06-30-0.35
Q1 '222022-03-31-0.76
Q4 '212021-12-31-0.98
Q3 '212021-09-30-1.50